PBMs, Policy, and the Human Cost of Delay in Metabolic Care
Episode Summary
Administrative barriers and benefit design delays in metabolic care restrict access to GLP-1 and incretin therapies, worsening diabetes and obesity outcomes while widening equity gaps.